On Monday, September 7, 2026, three developments touched GLP-1 access at once. Delaware lawmakers took up a bill aimed at pharmacy benefit managers, the companies that help set what patients pay at the pharmacy counter. At the same time, two separate lawsuits against Novo Nordisk moved forward in the courts, though their claims remain sealed. For anyone taking or considering Ozempic or Wegovy, these cases and this bill could affect access and cost in the months ahead.
Pharmacy benefit managers work between drug manufacturers, insurers, and pharmacies, and they influence which drugs a plan covers and how much a patient pays at the counter. Delaware Senate Bill 271 would amend Title 18 of the state code to place new requirements on how these managers operate. For patients using GLP-1 medications such as Ozempic or Wegovy, changes to PBM rules could affect whether a drug stays on a formulary or how a copay is calculated. The bill has not yet passed, so I would suggest following its progress rather than assuming any change to cost will happen soon. Delaware residents taking these medications may want to check back on the bill's status as it moves through the legislature.
One of the two lawsuits tracked this week names Norton as the plaintiff, and the case centers on a patient's use of Ozempic or Wegovy. The docket does not yet show the specific claims or allegations being made, so it is not possible to say what harm the patient alleges or what remedy is being sought. Lawsuits like this often take months before detailed filings become public, and the early stage of a case can mean little information is available to outside readers. Patients currently taking either medication do not need to change anything based on this filing alone, since no claims have been confirmed yet. I would suggest treating this case as one to watch rather than a reason for concern right now.
The second Novo Nordisk case tracked this week, Olvera v. Novo Nordisk, Inc., stands alongside Norton as one of two active filings against the company. Cases at this early stage sometimes remain sealed or simply have not been fully entered into the public docket yet, which is why no claims are listed. Two lawsuits filed close together against the same manufacturer can sometimes point to a broader pattern, though it is too early to draw that conclusion from what is public so far. Both cases may eventually be consolidated, amended, or dismissed, and none of those outcomes can be predicted from the current record. Readers who want more detail can follow the linked docket entries as they update, since new filings will state the claims once they become public.
None of these three developments have reached a final outcome yet, so the most useful step is to keep an eye on both tracks: the Delaware PBM bill and the two Novo Nordisk lawsuits. If you live in Delaware and take a GLP-1 medication, following the bill's progress through committee can help you understand any changes to cost or coverage before they take effect. If you are considering legal action related to Ozempic or Wegovy, or simply want to understand what these cases might mean, checking the linked docket entries periodically is a reasonable approach. Patient Lens will continue tracking each of these as new information becomes public.
Key details
Delaware lawmakers introduced a PBM bill that could change what patients pay for drugs.
A separate case, Norton v. Novo Nordisk, involves a patient suing over Ozempic or Wegovy.
In a third case, Olvera v. Novo Nordisk, the specific claims have not been made public.
Originally published on GLP1Laws.
Every Sunday, the weekly newsletter pulls the full week together: the news from GLP-1 Nation, the access updates from GLP1Laws, the latest GLP-1 Studio podcast episodes, and what changed in the Cozy Butter community.